Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Infectious Diseases and Respiratory Medicine, Charitéplatz 1, 10117, Berlin, Germany.
Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Infectious Diseases and Respiratory Medicine, Charitéplatz 1, 10117, Berlin, Germany; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany.
Respir Med. 2022 Oct;202:106968. doi: 10.1016/j.rmed.2022.106968. Epub 2022 Aug 28.
Cardiopulmonary Exercise Testing (CPET) provides a comprehensive assessment of pulmonary, cardiovascular and musculosceletal function. Reduced CPET performance could be an indicator for chronic morbidity after COVID-19.
Patients ≥18 years with confirmed PCR positive SARS-CoV-2 infection were offered to participate in a prospective observational study of clinical course and outcomes of COVID-19. 54 patients completed CPET, questionnaires on respiratory quality of life and performed pulmonary function tests 12 months after SARS-CoV-2 infection.
At 12 months after SARS-CoV-2 infection, 46.3% of participants had a peak performance and 33.3% a peak oxygen uptake of <80% of the predicted values, respectively. Further impairments were observed in diffusion capacity and ventilatory efficiency. Functional limitations were particularly pronounced in patients after invasive mechanical ventilation and extracorporeal membrane oxygenation treatment. Ventilatory capacity was reduced <80% of predicted values in 55.6% of participants, independent from initial clinical severity. Patient reported dyspnea and respiratory quality of life after COVID-19 correlated with CPET performance and parameters of gas exchange. Risk factors for reduced CPET performance 12 months after COVID-19 were prior intensive care treatment (OR 5.58, p = 0.004), SGRQ outcome >25 points (OR 3.48, p = 0.03) and reduced D (OR 3.01, p = 0.054).
Functional limitations causing chronic morbidity in COVID-19 survivors persist over 12 months after SARS-CoV-2 infection. These limitations were particularly seen in parameters of overall performance and gas exchange resulting from muscular deconditioning and lung parenchymal changes. Patient reported reduced respiratory quality of life was a risk factor for adverse CPET performance.
心肺运动测试(CPET)可全面评估肺、心血管和肌肉骨骼功能。CPET 表现降低可能是 COVID-19 后慢性发病的一个指标。
≥18 岁、经 PCR 确诊 SARS-CoV-2 感染阳性的患者被邀请参加一项前瞻性观察研究,以了解 COVID-19 的临床病程和结局。54 例患者在 SARS-CoV-2 感染后 12 个月完成了 CPET、呼吸质量问卷和肺功能测试。
在 SARS-CoV-2 感染后 12 个月时,分别有 46.3%和 33.3%的患者达到峰值运动能力和峰值摄氧量,低于预测值的 80%。进一步的弥散能力和通气效率受损。在接受有创机械通气和体外膜氧合治疗的患者中,功能障碍更为明显。在 55.6%的患者中,通气能力低于预测值的 80%,与初始临床严重程度无关。COVID-19 后患者报告的呼吸困难和呼吸质量与 CPET 表现和气体交换参数相关。COVID-19 后 12 个月 CPET 表现降低的危险因素为:重症监护治疗(OR 5.58,p=0.004)、SGRQ 结局>25 分(OR 3.48,p=0.03)和 D 值降低(OR 3.01,p=0.054)。
COVID-19 幸存者在 SARS-CoV-2 感染后 12 个月仍存在导致慢性发病的功能障碍。这些障碍在总体运动表现和气体交换参数中表现更为明显,这是由肌肉失健和肺实质改变导致的。患者报告的呼吸质量下降是 CPET 表现不良的危险因素。